propranolol has been researched along with atorvastatin in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (12.50) | 29.6817 |
| 2010's | 13 (81.25) | 24.3611 |
| 2020's | 1 (6.25) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Honda, K; Izumi, T; Miyaji, Y; Nakayama, S; Okazaki, O; Okudaira, N; Shiosakai, K; Sugiyama, D; Suzuki, W; Takakusa, H; Watanabe, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Buckley, DB; Funk, RS; Hensley, T; Kazmi, F; Loewen, GJ; Parkinson, A; Pope, C | 1 |
| Dalvie, D; Loi, CM; Smith, DA | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Chen, IJ; Hsieh, SL; Kwan, AL; Lin, HL; Shen, KP; Wu, BN | 1 |
| Dhull, P; Kumar, KV; Patnaik, SK; Upreti, V | 1 |
| Augustin, S; Esteban, R; Ezkurdia, N; Genescà, J; Martell, M; Raurell, I; Rodríguez, S | 1 |
| Ahammed, SM; Bishnu, S; Chatterjee, S; Chowdhury, A; Das, K; Dhali, GK; Hembram, J; Sarkar, A | 1 |
| Baiges, A; Bosch, J; Hernández-Gea, V | 1 |
| Beleford, DT; Diab, M; Long, RK; Malloy, MJ; Qubty, WF; Shieh, JT | 1 |
| Anghel, R; Forsea, L; Gales, L; Georgescu, M; Mitrea, D; Mitrica, R; Serbanescu, L; Stanculescu, I; Stefanica, I; Trifanescu, O | 1 |
3 review(s) available for propranolol and atorvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Pharmacologic prevention of variceal bleeding and rebleeding.
Topics: Adrenergic beta-Antagonists; Atorvastatin; Carbazoles; Carvedilol; Esophageal and Gastric Varices; Gastrointestinal Hemorrhage; Hemodynamics; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension, Portal; Incidence; Liver; Liver Cirrhosis; Nitric Oxide Synthase Type III; Portal Pressure; Propanolamines; Propranolol; Simvastatin; Splanchnic Circulation | 2018 |
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine | 2022 |
1 trial(s) available for propranolol and atorvastatin
| Article | Year |
|---|---|
Effects of atorvastatin on portal hemodynamics and clinical outcomes in patients with cirrhosis with portal hypertension: a proof-of-concept study.
Topics: Adrenergic beta-Antagonists; Adult; Antihypertensive Agents; Atorvastatin; Disease Progression; Drug Therapy, Combination; Female; Humans; Hypertension, Portal; India; Liver Cirrhosis; Male; Middle Aged; Portal Pressure; Proof of Concept Study; Propranolol; Prospective Studies; Single-Blind Method; Time Factors; Treatment Outcome | 2018 |
12 other study(ies) available for propranolol and atorvastatin
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Combination of GSH trapping and time-dependent inhibition assays as a predictive method of drugs generating highly reactive metabolites.
Topics: Glutathione; Pharmacology; Sulfur Radioisotopes | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells).
Topics: Adrenergic beta-Antagonists; Amines; Ammonium Chloride; Antidepressive Agents, Tricyclic; Atorvastatin; Cell Line, Transformed; Diuretics; Hepatocytes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Imipramine; Lysosomes; Monensin; Nigericin; Propranolol; Pyrroles | 2013 |
Which metabolites circulate?
Topics: Humans; Metabolic Clearance Rate; Pharmaceutical Preparations | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Eugenosedin-A prevents hyperglycaemia, hyperlipidaemia and lipid peroxidation in C57BL/6J mice fed a high-fat diet.
Topics: Adipose Tissue; Animals; Atorvastatin; Blood Glucose; Body Weight; Brain; Dietary Fats; Female; Glutathione Peroxidase; Heptanoic Acids; Hyperglycemia; Hyperlipidemias; Insulin; Ketanserin; Lipid Peroxidation; Lipogenesis; Liver; Malondialdehyde; Mice; Mice, Inbred C57BL; Piperazines; PPAR gamma; Prazosin; Propranolol; Pyrroles; Superoxide Dismutase; Weight Gain | 2009 |
An unusual cause of delayed puberty: Berardinelli- Seip syndrome.
Topics: Administration, Cutaneous; Adolescent; Atorvastatin; Combined Modality Therapy; Diet, Fat-Restricted; Drug Therapy, Combination; Estrogens; Exercise Therapy; Female; Fenofibrate; Fish Oils; Heptanoic Acids; Humans; Hypertension, Portal; Hypertriglyceridemia; Insulin; Insulin Resistance; Lipodystrophy, Congenital Generalized; Pioglitazone; Propranolol; Puberty, Delayed; Pyrroles; Thiazolidinediones; Treatment Outcome | 2012 |
The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
Topics: Adrenergic beta-Antagonists; Animals; Atorvastatin; Bilirubin; Carbazoles; Carvedilol; Creatinine; Droxidopa; Drug Evaluation, Preclinical; Drug Therapy, Combination; Hemodynamics; Heptanoic Acids; Liver Cirrhosis, Experimental; Mesenteric Artery, Superior; Osmolar Concentration; Portal Pressure; Potassium; Propanolamines; Propranolol; Pyrroles; Rats; Serum Albumin; Sodium; Vascular Resistance | 2015 |
Schimke immunoosseous dysplasia and management considerations for vascular risks.
Topics: Anticholesteremic Agents; Antihypertensive Agents; Arteriosclerosis; Atorvastatin; Benzazepines; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Child; Disease Management; DNA Helicases; Dyslipidemias; Female; Gene Expression; Headache; Humans; Hypertension; Mutation; Nephrotic Syndrome; Osteochondrodysplasias; Primary Immunodeficiency Diseases; Propranolol; Pulmonary Embolism | 2019 |